https://alectinibinhibitor.com..../effect-of-covering-
The JADER database contained 534 688 reports from April 2004 to June 2018. The RORs of pneumonitis including interstitial lung condition for nivolumab, pembrolizumab, and ipilimumab were 7.02 (95% confidence period 6.55-7.52), 9.08 (8.28-9.97), and 1.74 (1.27-2.38), respectively. The median onsets (quartiles, 25-75%) of myocarditis brought on by nivolumab and pembrolizumab were 28.0 (15.5-60.5) and 18.0 (13.0-44.5) days, respectively. Co-therapy with nivolumab and ipilimumab may be related to irAEs in ma
Like
Comment
Share
